Origami Therapeutics is now on Y Combinator! Learn more about Y Combinator Funded Companies

Developing Curative Medicines for Neurodegenerative Diseases

Our CEO, Beth Hoffman, shares some of her insights into how to approach novel CNS targets by targeting the root cause in order to to slow or halt disease progression on pg. 24 of the latest issue of California Life Sciences digital magazine, Life Sciences Insights....

Attacking Neurodegenerative Diseases with Protein Degraders

The use of protein degraders is a promising area of emerging small molecule therapies. Rather than inhibit disease-causing proteins, degraders use a natural cellular process to break them down. Origami Therapeutics is using its proprietary drug discovery platform to...

Origami Brings Protein Degradation to Neurodegenerative Disorders

Protein degradation is an up-and-coming approach that most often is used in oncology. Now, Origami Therapeutics is among the first to apply it to genetic neurodegenerative disorders, targeting proteins that otherwise have been considered undruggable. Read full article

Founder Spotlight #36: Beth Hoffman @ Origami Therapeutics

Beth Hoffman is Founder, President, & CEO @ Origami Therapeutics. She brings more than 25 years experience of CNS drug discovery and has developed over 30 assets that have advanced into the clinic in cystic fibrosis, metabolic diseases, neurology, pain, and...

Origami named part of the W22 Batch at Y Combinator

Oral drugs to halt neurodegeneration Origami Therapeutics, Inc. is a biotech company developing novel protein degraders with potential to delay or halt disease progression by eliminating toxic proteins from the body. Our drug discovery platform leverages our...

Other events happening for Origami

28 Feb – 3 March, 2022 Presenting at 17th Annual Huntington’s Disease Therapeutics Conference   28-30 March, 2022 Presenting at 10th Annual Neurodegenerative Drug Development Summit...

MedCity News Article

Origami Therapeutics developing treatments for neurodegenerative diseases with ML and computational chemistry. Learn more

BioCentury Article

Emerging Company Profile – Origami: Correcting or eliminating misfolded proteins. Learn More